Patient perspective on remote monitoring of cardiovascular implantable electronic devices: rationale and design of the REMOTE-CIED study by H. Versteeg et al.
DESIGN STUDYARTICLE
Patient perspective on remote monitoring of cardiovascular
implantable electronic devices: rationale and design
of the REMOTE-CIED study
H. Versteeg & S. S. Pedersen & M. H. Mastenbroek &
W. K. Redekop & J. O. Schwab & P. Mabo & M. Meine
Published online: 19 August 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Background Remote patient monitoring is a safe and effective
alternative for the in-clinic follow-up of patients with cardio-
vascular implantable electronic devices (CIEDs). However,
evidence on the patient perspective on remote monitoring is
scarce and inconsistent.
Objectives The primary objective of the REMOTE-CIED
study is to evaluate the influence of remote patient monitoring
versus in-clinic follow-up on patient-reported outcomes. Sec-
ondary objectives are to: 1) identify subgroups of patients who
may not be satisfied with remote monitoring; and 2) investi-
gate the cost-effectiveness of remote monitoring.
Methods The REMOTE-CIED study is an international
randomised controlled study that will include 900 consecutive
heart failure patients implanted with an implantable
cardioverter defibrillator (ICD) compatible with the Boston
Scientific LATITUDE® Remote Patient Management system
at participating centres in five European countries. Patients
will be randomised to remote monitoring or in-clinic follow-
up. The In-Clinic group will visit the outpatient clinic every 3–
6 months, according to standard practice. The Remote Mon-
itoring group only visits the outpatient clinic at 12 and
24 months post-implantation, other check-ups are performed
remotely. Patients are asked to complete questionnaires at five
time points during the 2-year follow-up.
Conclusion The REMOTE-CIED study will provide insight
into the patient perspective on remote monitoring in ICD
patients, which could help to support patient-centred care in
the future.
Keywords REMOTE-CIED . Cardiovascular implantable
electronic devices . Remotemonitoring . Patient-reported
outcomes . Cost-effectiveness
Introduction
Given the growth in the number of patients receiving a car-
diovascular implantable electronic device (CIED), in particu-
lar the implantable cardioverter defibrillator (ICD) and cardiac
resynchronisation therapy (CRT) devices, the burden on out-
patient clinics to follow up these patients is increasing [1–3].
Remote patient monitoring offers a potential solution to this
problem [4]. Remote monitoring systems contain a home
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transmitter that interrogates the CIED at pre-specified time
points and sends the acquired data (e.g. information on battery
status, lead impedances) from the patient’s home to the hos-
pital, hereby avoiding or reducing the number of unnecessary
in-clinic visits. In between these scheduled remote follow-ups,
the transmitter sends information to the physician on technical
(e.g., device integrity) or clinical (e.g., arrhythmias) issues,
which are checked regularly [4]. Besides device parameters,
some remote monitoring systems include tools to monitor the
clinical status of the patient, such as fluid status, weight and
blood pressure. By frequent assessment of these parameters,
remote monitoring allows the early detection of heart failure
worsening which might prevent hospitalisations [5].
Multiple large-scale clinical trials in ICD patients have
shown that remote monitoring significantly reduces the num-
ber of in-clinic visits, without impairing patient safety [6].
Additionally, remote patient monitoring reduces the time from
onset of events (e.g. arrhythmias and device malfunctions) to
clinical decision-making compared with conventional in-
clinic follow-ups, which may also lead to a reduction in ICD
shocks [6, 7]. Most current ICDs are capable of remote mon-
itoring and several professional societies recommend the rou-
tine use of remote monitoring in clinical practice [2, 4].
Recent surveys in the United States and Europe demon-
strated that although the use of remote monitoring is growing,
overall adaptation remains low and varies considerably be-
tween hospitals [8, 9]. Impediments to implementation in-
clude the absence of national guidelines and reimbursement
models for remote monitoring in clinical practice [4, 6, 9–11].
Also, remote monitoring is unlikely to become the standard of
care until it is conclusively demonstrated that patient outcome
is favourably affected [12, 13]. Whether clinical effects of
remote monitoring translate into improved patient-reported
outcomes such as symptoms, quality of life and satisfaction
with care, and whether patients are more satisfied with remote
monitoring than in-clinic follow-up has received little
attention.
To date, the few randomised controlled trials on remote
monitoring in ICD patients that included patient-reported
outcomes have yielded inconsistent results [14–16]. Prospec-
tive cohort studies using short ad hoc questionnaires have
reported that 60–95 % of ICD patients are highly satisfied
with remote monitoring and that it makes them feel safe
[17–22]. However, these studies provided no information on
how many patients refused to use a remote monitoring system
and preferred to be checked at the outpatient clinic. This is
essential, as a recent registry study from the United States
showed that 24 % of the patients who received a remote
monitoring system did not activate it [8].
No prospective randomised study has examined whether
there is a subset of patients whomight not benefit from remote
monitoring in terms of patient-reported outcomes and might
be more satisfied with standard clinical follow-up visits. For
example, a substantial number of ICD patients report in-
creased emotional distress, such as anxiety and depression
[23]. The remote monitoring system might provide these
patients with a sense of security, but on the other hand the
system may act as a constant reminder of their device and
underlying disease. Also, patients might miss the personal
attention and reassurance from their treating physician and
heart failure team [24]. A qualitative study on ICD patients
who received a remote monitoring system showed that
nonusers believed that in-clinic visits are psychologically
advantageous and trusted the healthcare professionals over
technology when it came to managing their health [25].
The international REMOTE-CIED study is the first pro-
spective, randomised controlled study primarily designed to
examine the patient perspective on remote monitoring in ICD
patients, in order to enhance the patient-centredness of care in
this patient group. The primary study objective is to evaluate
the influence of remote patient monitoring versus convention-
al in-clinic follow-up on patient-reported outcomes, by means
of standardised and validated questionnaires. Secondary ob-
jectives are to (1) identify subgroups of patients who might
not be satisfied with remote monitoring and examine if they
are distinguishable based on their demographic, clinical, or
psychological profile; and (2) investigate the cost-
effectiveness of remote monitoring + in-clinic follow-up as
compared with in-clinic follow-up only.
Methods
Study design
The REMOTE-CIED study is a multicentre, prospective,
randomised controlled study, with patients being recruited
from five European countries (i.e., France, Germany, Spain,
Switzerland and the Netherlands). The University Medical
Centre Utrecht, the Netherlands, is the legal sponsor, and
responsible for developing, implementing and managing the
study in accordance with the protocol and all applicable laws
and regulations. The study protocol has been approved by the
medical ethics committees of the participating centres.
Study population
Consecutive patients receiving an ICD or CRT-
defibrillator (CRT-D) at one of the participating centres will
be screened for study participation. Patients implanted with a
first-time (primary or secondary prophylactic) ICD or CRT-D
compatible with the LATITUDE® Patient Management sys-
tem from Boston Scientific, with left ventricular ejection
fraction ≤35 % and symptomatic heart failure (New York
Heart Association functional class II or III) at the time of
implantation, and providing written informed consent will be
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eligible to participate. Patients will be excluded if they are
younger than 18 or older than 85 years of age, on the waiting
list for heart transplantation, have a history of psychiatric
illness other than affective/anxiety disorders, or are unable to
complete the questionnaires due to cognitive impairments or
insufficient knowledge of the language.
Study procedure, randomisation and follow-up
When scheduled for device implantation, eligible patients
receive a letter describing the purpose, design and possible
benefits/risks of the study. Patients willing to participate are
asked to sign an informed consent form. Of note, study refusal
or withdrawal due to the patient having a strong preference for
remote monitoring or in-clinic follow-up will be registered.
At discharge from hospital after implantation, included
patients receive the baseline questionnaire and are asked to
complete this 1 to 2 weeks after implantation (T0) to avoid
measuring preoperative distress. When the completed T0
questionnaire is received at Tilburg University–which serves
as core lab for the patient-reported outcomes–patients are
randomised in a 1:1 fashion to either remote patient monitor-
ing+in-clinic follow-up (RPM group) or in-clinic follow-up
only (In-Clinic group) with the use of a blocked randomisation
procedure. To ensure that the relative percentage of ICD and
CRT-D patients is equal in both groups, we use separate
randomisation procedures within these two subsets of
patients.
Four to 8 weeks after implantation (preferably during the
first in-clinic visit for assessment of wound healing etc.),
patients in the RPM group will receive the remote monitoring
system and be instructed how to install and use it. In accor-
dance with the ACC/AHA/HRS guidelines, patients
randomised to this group will visit the outpatient clinic again
at 12 and 24 months after implantation [2]. The intermediate
check-ups will be performed remotely. Patients randomised to
the In-Clinic group will be followed up according to standard
practice at the participating centres and visit the outpatient
clinic (at least) every 3–6 months during the study. For pa-
tients in both groups, the follow-up assessments will take
place at 3 (T1), 6 (T2), 12 (T3), and 24 (T4) months post-
implantation. A schematic representation of the study design
is shown in Fig. 1.
Measures
Primary endpoints are patient-reported heart failure-specific
health status (i.e., symptoms, functioning and quality of life),
ICD acceptance and satisfaction with care. To assess these
patient-reported outcomes and potentially associated psycho-
logical factors (i.e., Type D personality, psychological dis-
tress), patients in both groups will complete a number of
questionnaires at the five assessment times (Table 1). All
questionnaires are standardised and validated, except for the
questionnaires used to assess patient satisfaction with remote
monitoring, and their productivity and healthcare utilisation
for cost-effectiveness. For these purposes, new questionnaires
were developed.
Information on clinical characteristics and outcomes, in-
cluding disease status, comorbidities, use of cardiac and psy-
chotropic medication, ventricular arrhythmias, appropriate
Hospitalisation for  ICD/CRT-D implantation
Informed Consent
At discharge, patients receive T0 questionnaire
2-4 weeks
Completed T0 questionnaire received at 
Tilburg University: 









Remote check-up    
T2 questionnaire
12 months












In-clinic check-up                   
T2 questionnaire
12 months




In-clinic check-up                  
T4 questionnaire
Fig. 1 Schematic representation of the study design
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and inappropriate ICD therapy, in-clinic visits, hospital ad-
missions, and mortality will be obtained from patients’ med-
ical records or through device interrogation and gathered via
electronic case report forms (Research Online) at baseline
(T0), 6 (T2), 12 (T3) and 24 (T4) months after implantation.
Remote patient monitoring system
Four to 8 weeks after implantation, patients randomised to the
RPM group will receive the LATITUDE® Patient Manage-
ment system, including weight scale and blood pressure cuffs,
and will be instructed by an experienced ICD technician/nurse
at the centre how to install and use it.
The LATITUDE® Patient Management system consists of
a wireless communicator, a piece of equipment in the patients’
home, which is intended to remotely communicate with a
compatible CIED from Boston Scientific and transfer data to
a central database. The information gathered by the commu-
nicator is accessible to the patient’s healthcare team via the
secured LATITUDE® website. Through the website, the cli-
nician sets two automatic device interrogation schedules: (1)
Remote device follow-ups: information similar to that of an
in-clinic device interrogation is collected, including a real-
time electrocardiogram (ECG), tests of battery status, lead
impedances, and sensing amplitude; (2) Remote monitoring:
during and in-between follow-ups, the clinic is notified when
a predefined alert is detected. The communicator provides two
levels of alerts: (a) red alerts indicate urgent conditions such as
low life battery, low or high shock lead impedance, and
possible device malfunction; (b) yellow alerts can be selected
by the clinician and include various indications such as ex-
plant indicator reached, arrhythmias, and weight change. The
clinician can also control patient-initiated, off-cycle data trans-
mission if the patient needs to send data other than during
routine follow-up or monitoring, for example in case of an
ICD shock.
The LATITUDE® Heart Failure Management system in-
cludes tools to monitor the patient’s disease status. Patients
can measure their weight and blood pressure by using the
external weight scale and blood pressure monitor. These data
are transmitted wirelessly to the LATITUDE® communicator.
Beside actions and measurements within the scope of this
study, patients are treated according to the standard practice of
their ICD centre.
Sample size calculation and statistical analyses
The number of patients required to provide sufficient power to
test the first objective of the proposed study was derived from
a power analysis based on a small expected between-group
effect size of .20, as measured with Cohen’s d. With alpha =
0.05 and power = 0.85 (two-sided test), 900 patients are
needed (i.e., 450 in each group). The data will be analysed
according to the intention-to-treat principle, with the inclusion
of all randomised patients in the statistical analysis regardless
of whether they completed the study.
Univariable and multivariable linear and logistic regression
analyses will be performed to examine the group effects on
Table 1 Patient-reported outcomes and psychological factors assessed in the study
Construct Questionnaire T0 T1 T2 T3 T4
Outcome measures
Health status Kansas City Cardiomyopathy Questionnaire (KCCQ) x x x x x
Device acceptance Florida Patient Acceptance Survey (FPAS) x x x x x
Satisfaction with care Visual analogue scale (0–100) x x x x x
Satisfaction with remote monitoringa Purpose-designed questionnaire x x x x
Cost-effectiveness: QALY Euroqol 5D (EQ-5D) + VAS scale x x x x x
Cost-effectiveness: productivity and health care utilisation Purpose-designed questionnaire x x x x
Psychological variables
ICD concerns ICD Patient Concerns Questionnaire (ICDC) x x x x
ICD expectationsb Expectations regarding ICD x
Illness perception Illness Perceptions Questionnaire (IPQ) x x
Anxiety symptoms Generalised Anxiety Disorder (GAD-7) x x x
Depressive symptoms Patient Health Questionnaire (PHQ-9) x x x
Type D personality Type D Scale (DS14) x
Self-care behaviour European Heart Failure Self Care Behaviour Scale (EHFScBS) x x x
T0 = Baseline; T1 = 3 months; T2 = 6 months; T3 = 12 months; T4 = 24 months
ICD implantable cardioverter defibrillator; QALY quality-adjusted life year; VAS visual analogue scale
a Patients in RPM group only
bDutch patients only
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health status, device acceptance and satisfaction with care at
several points in time. Analysis of (co)variance with repeated
measures will be performed to assess between-group differ-
ences in changes in these patient-reported outcomes over
2 years.
Patients’ answers on the ‘Satisfaction with remote moni-
toring’ questionnaire will be used to classify them into sub-
groups of patients that are/are not satisfied with remote mon-
itoring. Chi-square tests and Student’s t-tests (or a non-
parametric equivalent if necessary) will be performed to ex-
plore the demographic, clinical, and psychological character-
istics of the patients in these subgroups. Also, multivariable
logistic and linear regression analyses will be performed to
examine which factors are independently associated with sat-
isfaction with remote monitoring as a dichotomous outcome
(satisfied: yes/no) and as a continuous outcome (satisfaction
visual analogue scale 0–10), respectively.
To determine the cost-effectiveness, both short-term and
long-term country-specific cost-effectiveness analyses will be
performed. The short-term analysis has a 2-year time horizon,
while the long-term analysis will have a lifetime horizon. Data
used for the short-term analysis will be based on the data
captured during the trial, while data used for the long-term
analysis will consist of a combination of trial data and data
from other sources. These data will be combined using a
disease progression and treatment model and will be analysed
using probabilistic analyses, sensitivity analyses, and scenario
analyses. The primary cost-effectiveness outcome will be the
incremental cost per quality-adjusted life year (QALY)
gained.
Discussion
Large-scale trials have shown that remote patient monitoring
is a safe, effective and timely alternative for conventional in-
clinic follow-up of ICD/CRT-D patients [6]. However, these
trials have fallen short in their patient-centredness and have
left an important question unanswered: namely, what do pa-
tients think about remote monitoring [12]? To date, evidence
on the patient perspective on remote monitoring is scarce and
inconsistent. As emphasised in a recent scientific statement
from the American Heart Association, the assessment of
patient-reported outcomes such as patient-reported health sta-
tus is essential to enhance the patient-centredness of
care and better characterise the impact of healthcare
delivery on patient health [26]. No study has examined
whether there is a subset of patients who might not
benefit from remote monitoring in terms of patient-
reported outcomes and would be more satisfied with
standard clinical follow-up visits, and whether they are
distinguishable based on their demographic, clinical, or
psychological profile. The REMOTE-CIED study is an
international, prospective randomised controlled study
specifically designed to provide more insight into the
patient perspective on and cost-effectiveness of remote
monitoring compared with in-clinic follow-up in ICD/
CRT-D patients. This study will be able to show how
patients feel about remote monitoring and determine
whether there are subgroups of patients that might be
better served by receiving in-clinic follow-up visits. The
study aims to include 900 consecutive patients from five
European countries, who will be followed-up for 2 years
post-implantation.
Conclusion
The international REMOTE-CIED study is the first
prospective randomised controlled study that primarily
aims to assess the effect of remote patient monitoring
on patient-reported outcomes in ICD patients, which
could help to support patient-centred care in the future.
The study is currently recruiting patients and results
are expected in 2017.
Registration The REMOTE-CIED study is registered at
ClinicalTrials.gov with study ID NCT01691586.
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